Arthritis drug restores 100% of hair on some patients with severe alopecia in global trial

Arlene faced a devastating blow when she lost almost all of her hair to alopecia areata, an autoimmune disorder that mistakenly attacks hair follicles. Despite the emotional toll it took on her confidence and mental health, researchers at Harvard University found a potential solution in an unexpected place: upadacitinib, a drug initially developed to treat arthritis.

This once-daily oral medication, which blocks a specific cellular signal in the JAK/STAT pathway that drives inflammation, showed promise in restoring hair growth for severe cases of alopecia areata. In two large, international clinical trials, researchers recruited patients with severe alopecia areata who had lost an average of 84% of their scalp hair.

Participants took either upadacitinib at 15mg or 30mg doses, or a placebo daily for 24 weeks. Remarkably, roughly half of all participants who took upadacitinib saw at least 80% of their scalp hair regrow, with 35% of those on the 15mg dose and 46% on the 30mg dose achieving "deep regrowth" – more than 90% coverage. Incredibly, about 20% of participants reached a score of zero on the standard hair-loss scale, indicating a completely full head of hair.

Mostaghimi, the study's lead author and associate professor of dermatology at Brigham and Women's Hospital, noted that upadacitinib demonstrated both rapid onset and substantial depth of response as a treatment for alopecia areata. While not yet approved specifically for the condition, these results offer a glimmer of hope for individuals struggling with severe hair loss.